Cargando…
A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis
Background: This clinical trial evaluated the pharmacokinetics and safety/tolerability of inhaled pirfenidone solution in volunteers and patients with idiopathic pulmonary fibrosis (IPF). Methods: Forty-four adults in six cohorts consented to receive single doses of a 12.5 mg/mL pirfenidone solution...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7041323/ https://www.ncbi.nlm.nih.gov/pubmed/30698487 http://dx.doi.org/10.1089/jamp.2018.1507 |
_version_ | 1783501138143739904 |
---|---|
author | Khoo, Jun Keng Montgomery, A. Bruce Otto, Kelly L. Surber, Mark Faggian, Jessica Lickliter, Jason D. Glaspole, Ian |
author_facet | Khoo, Jun Keng Montgomery, A. Bruce Otto, Kelly L. Surber, Mark Faggian, Jessica Lickliter, Jason D. Glaspole, Ian |
author_sort | Khoo, Jun Keng |
collection | PubMed |
description | Background: This clinical trial evaluated the pharmacokinetics and safety/tolerability of inhaled pirfenidone solution in volunteers and patients with idiopathic pulmonary fibrosis (IPF). Methods: Forty-four adults in six cohorts consented to receive single doses of a 12.5 mg/mL pirfenidone solution or placebo to assess tolerability and pharmacokinetics. Cohorts 1, 2, and 3 (normal healthy volunteers [NHV]) (n = 6 active; n = 2 placebo in each cohort) received 25, 50, and 100 mg pirfenidone, respectively. Cohort 4 (NHV) (n = 6 all active) received 100 mg of pirfenidone and underwent bronchoalveolar lavage (BAL) to measure epithelial lining fluid (ELF) pirfenidone concentrations. Cohort 5 (prior or current smokers with greater than 20 pack-year use) (n = 6 active; n = 2 placebo) and Cohort 6 (IPF patients) (n = 6 all active) received 100 mg of pirfenidone. All treatments were administered with an Investigational eFlow(®) Nebulizer System (PARI Pharma GmbH). Serial measures of urine and plasma pirfenidone were collected during the 24-hour postdose in all subjects. Results: Administration time ranged from 1.4 to 2 min/mL. No clinically relevant adverse effects on respiratory rate, spirometry, or oxygenation were observed. Drug-related adverse events were predominantly cough, n = 8/44 (one in IPF cohort), all mild, transient, and not dose limiting. Mean plasma pirfenidone Cmax levels in the 25, 50, 100 mg NHV, 100 mg smoker, and IPF cohorts were 202, 292, 802, 1370, 1016, and 1026 ng/mL, respectively. BAL cohort estimated ELF Cmax was 135.9 ± 54.5 μg/mL. In the BAL and IPF cohorts, 24-hour urine excretion of pirfenidone and metabolites data suggests similar alveolar deposition. Conclusions: Aerosol pirfenidone was well tolerated in normal volunteers, smokers, and IPF patients. High ELF concentrations were achieved in NHV with a 100 mg nebulizer dose. The 100 mg nebulizer dose averaged a 15-fold lower systemic pirfenidone exposure than reported with oral administration of the licensed oral dose. |
format | Online Article Text |
id | pubmed-7041323 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Mary Ann Liebert, Inc., publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-70413232020-02-26 A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis Khoo, Jun Keng Montgomery, A. Bruce Otto, Kelly L. Surber, Mark Faggian, Jessica Lickliter, Jason D. Glaspole, Ian J Aerosol Med Pulm Drug Deliv Original Research Background: This clinical trial evaluated the pharmacokinetics and safety/tolerability of inhaled pirfenidone solution in volunteers and patients with idiopathic pulmonary fibrosis (IPF). Methods: Forty-four adults in six cohorts consented to receive single doses of a 12.5 mg/mL pirfenidone solution or placebo to assess tolerability and pharmacokinetics. Cohorts 1, 2, and 3 (normal healthy volunteers [NHV]) (n = 6 active; n = 2 placebo in each cohort) received 25, 50, and 100 mg pirfenidone, respectively. Cohort 4 (NHV) (n = 6 all active) received 100 mg of pirfenidone and underwent bronchoalveolar lavage (BAL) to measure epithelial lining fluid (ELF) pirfenidone concentrations. Cohort 5 (prior or current smokers with greater than 20 pack-year use) (n = 6 active; n = 2 placebo) and Cohort 6 (IPF patients) (n = 6 all active) received 100 mg of pirfenidone. All treatments were administered with an Investigational eFlow(®) Nebulizer System (PARI Pharma GmbH). Serial measures of urine and plasma pirfenidone were collected during the 24-hour postdose in all subjects. Results: Administration time ranged from 1.4 to 2 min/mL. No clinically relevant adverse effects on respiratory rate, spirometry, or oxygenation were observed. Drug-related adverse events were predominantly cough, n = 8/44 (one in IPF cohort), all mild, transient, and not dose limiting. Mean plasma pirfenidone Cmax levels in the 25, 50, 100 mg NHV, 100 mg smoker, and IPF cohorts were 202, 292, 802, 1370, 1016, and 1026 ng/mL, respectively. BAL cohort estimated ELF Cmax was 135.9 ± 54.5 μg/mL. In the BAL and IPF cohorts, 24-hour urine excretion of pirfenidone and metabolites data suggests similar alveolar deposition. Conclusions: Aerosol pirfenidone was well tolerated in normal volunteers, smokers, and IPF patients. High ELF concentrations were achieved in NHV with a 100 mg nebulizer dose. The 100 mg nebulizer dose averaged a 15-fold lower systemic pirfenidone exposure than reported with oral administration of the licensed oral dose. Mary Ann Liebert, Inc., publishers 2020-02-01 2020-01-30 /pmc/articles/PMC7041323/ /pubmed/30698487 http://dx.doi.org/10.1089/jamp.2018.1507 Text en © Jun Keng Khoo, et al., 2020. Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. |
spellingShingle | Original Research Khoo, Jun Keng Montgomery, A. Bruce Otto, Kelly L. Surber, Mark Faggian, Jessica Lickliter, Jason D. Glaspole, Ian A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis |
title | A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis |
title_full | A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis |
title_fullStr | A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis |
title_full_unstemmed | A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis |
title_short | A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis |
title_sort | randomized, double-blinded, placebo-controlled, dose-escalation phase 1 study of aerosolized pirfenidone delivered via the pari investigational eflow nebulizer in volunteers and patients with idiopathic pulmonary fibrosis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7041323/ https://www.ncbi.nlm.nih.gov/pubmed/30698487 http://dx.doi.org/10.1089/jamp.2018.1507 |
work_keys_str_mv | AT khoojunkeng arandomizeddoubleblindedplacebocontrolleddoseescalationphase1studyofaerosolizedpirfenidonedeliveredviathepariinvestigationaleflownebulizerinvolunteersandpatientswithidiopathicpulmonaryfibrosis AT montgomeryabruce arandomizeddoubleblindedplacebocontrolleddoseescalationphase1studyofaerosolizedpirfenidonedeliveredviathepariinvestigationaleflownebulizerinvolunteersandpatientswithidiopathicpulmonaryfibrosis AT ottokellyl arandomizeddoubleblindedplacebocontrolleddoseescalationphase1studyofaerosolizedpirfenidonedeliveredviathepariinvestigationaleflownebulizerinvolunteersandpatientswithidiopathicpulmonaryfibrosis AT surbermark arandomizeddoubleblindedplacebocontrolleddoseescalationphase1studyofaerosolizedpirfenidonedeliveredviathepariinvestigationaleflownebulizerinvolunteersandpatientswithidiopathicpulmonaryfibrosis AT faggianjessica arandomizeddoubleblindedplacebocontrolleddoseescalationphase1studyofaerosolizedpirfenidonedeliveredviathepariinvestigationaleflownebulizerinvolunteersandpatientswithidiopathicpulmonaryfibrosis AT lickliterjasond arandomizeddoubleblindedplacebocontrolleddoseescalationphase1studyofaerosolizedpirfenidonedeliveredviathepariinvestigationaleflownebulizerinvolunteersandpatientswithidiopathicpulmonaryfibrosis AT glaspoleian arandomizeddoubleblindedplacebocontrolleddoseescalationphase1studyofaerosolizedpirfenidonedeliveredviathepariinvestigationaleflownebulizerinvolunteersandpatientswithidiopathicpulmonaryfibrosis AT khoojunkeng randomizeddoubleblindedplacebocontrolleddoseescalationphase1studyofaerosolizedpirfenidonedeliveredviathepariinvestigationaleflownebulizerinvolunteersandpatientswithidiopathicpulmonaryfibrosis AT montgomeryabruce randomizeddoubleblindedplacebocontrolleddoseescalationphase1studyofaerosolizedpirfenidonedeliveredviathepariinvestigationaleflownebulizerinvolunteersandpatientswithidiopathicpulmonaryfibrosis AT ottokellyl randomizeddoubleblindedplacebocontrolleddoseescalationphase1studyofaerosolizedpirfenidonedeliveredviathepariinvestigationaleflownebulizerinvolunteersandpatientswithidiopathicpulmonaryfibrosis AT surbermark randomizeddoubleblindedplacebocontrolleddoseescalationphase1studyofaerosolizedpirfenidonedeliveredviathepariinvestigationaleflownebulizerinvolunteersandpatientswithidiopathicpulmonaryfibrosis AT faggianjessica randomizeddoubleblindedplacebocontrolleddoseescalationphase1studyofaerosolizedpirfenidonedeliveredviathepariinvestigationaleflownebulizerinvolunteersandpatientswithidiopathicpulmonaryfibrosis AT lickliterjasond randomizeddoubleblindedplacebocontrolleddoseescalationphase1studyofaerosolizedpirfenidonedeliveredviathepariinvestigationaleflownebulizerinvolunteersandpatientswithidiopathicpulmonaryfibrosis AT glaspoleian randomizeddoubleblindedplacebocontrolleddoseescalationphase1studyofaerosolizedpirfenidonedeliveredviathepariinvestigationaleflownebulizerinvolunteersandpatientswithidiopathicpulmonaryfibrosis |